文献速递肾小球疾病遗传性与小管间质肾病

达雷妥尤单抗治疗单克隆免疫球蛋白沉积性增生性肾小球肾炎的安全性与疗效

Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits.
PubMed 文献 · J Am Soc Nephrol · 2021-03-08

这项开放标签2期试验评估了达雷妥尤单抗在11例PGNMID和1例伴单克隆丙种球蛋白病的C3肾小球病成人中的安全性与疗效。10例接受至少一剂PGNMID患者中6例部分缓解、4例完全缓解,总缓解率100%,蛋白尿中位值从4346 mg/d降至12个月时1264 mg/d,肾功能稳定。

要点

  • 达雷妥尤单抗在PGNMID中总缓解率达100%,蛋白尿显著下降且肾功能稳定。
  • 安全性可接受,发生5例严重不良事件,3例复发后重启治疗2例再获部分缓解。
  • 该药值得进一步研究用于PGNMID治疗。

核心结论

  • 达雷妥尤单抗安全性可接受,显著改善PGNMID患者蛋白尿并稳定肾功能,值得进一步研究。

研究设计与样本

  • 开放标签2期试验纳入11例PGNMID和1例伴单克隆丙种球蛋白病的C3肾小球病成人。
  • 入组条件为eGFR>20 ml/min/1.73 m2且蛋白尿>1 g/d。
  • 达雷妥尤单抗静脉16 mg/kg每周一次共8周,之后每两周一次共8次。
  • 主要结局为安全性(重大感染、3或4级贫血、白细胞减少或血小板减少)。

主要发现

  • 10例接受至少一剂达雷妥尤单抗的PGNMID患者中6例部分缓解、4例完全缓解,总缓解率100%。
  • 3例复发,其中2例重启达雷妥尤单抗后再次部分缓解。
  • 蛋白尿中位值从4346 mg/d降至12个月时1264 mg/d。
  • 发生5例严重不良事件。

关键数值与推荐

  • 完全缓解定义为蛋白尿<500 mg/d且eGFR较基线下降<15%。
  • 部分缓解定义为24小时蛋白尿下降>50%且eGFR下降<30%。

临床怎么用

  • 达雷妥尤单抗可作为PGNMID伴单克隆丙种球蛋白病患者的潜在治疗选择,需监测感染和血液学毒性。

局限性

  • 样本量小(11例PGNMID和1例C3G),为开放标签2期试验。
  • 1例C3G患者肾小球肾炎与单克隆丙种球蛋白病无关,1例PGNMID未完成首次输注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of proliferative GN with monoclonal Ig deposits (PGNMID) is not established. A monoclonal anti-CD38 antibody (daratumumab) is effective in treating multiple myeloma. Abnormal plasma cell clones may play a role in the pathogenesis of PGNMID. METHODS: We evaluated daratumumab's safety and efficacy in an open-label, phase 2 trial in 11 adults with PGNMID and one with C3 glomerulopathy (C3G) with monoclonal gammopathy. Patients had an eGFR >20 ml/min per 1.73 m2 and proteinuria >1 g/d. They received daratumumab intravenously (16 mg/kg) once weekly for 8 weeks, and then every other week for eight additional doses. Primary outcome was safety, defined as major infections, grade 3 or 4 anemia, leukopenia, or thrombocytopenia. Secondary outcomes were rate of complete remission (proteinuria <500 mg/d with <15% decline in baseline eGFR) or partial remission (>50% reduction in 24-hour proteinuria with <30% decline in eGFR) and proteinuria at 6 and 12 months. RESULTS: One patient with C3G had GN unrelated to the monoclonal gammopathy, and one with PGNMID did not complete the first infusion. Five serious adverse events occurred. During the 12 months of the trial, six of the ten patients with PGNMID who received at least one dose of daratumumab had a partial response, and four had a complete response (an overall response rate of 100%). Three patients experienced relapse, two of whom re-entered partial remission after resuming daratumumab therapy. Proteinuria declined significantly, from a median of 4346 mg/d to 1264 mg/d by 12 months. CONCLUSIONS: Daratumumab demonstrated an acceptable safety profile and resulted in significant improvement in proteinuria while stabilizing kidney function in patients with PGNMID, suggesting the drug merits further investigation. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Daratumumab in Treatment of PGNMID and C3 GN, NCT03095118.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zand L, Rajkumar SV, Leung N, et al. Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. J Am Soc Nephrol. 2021. PMID: 33685975. doi:10.1681/ASN.2020101541

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。